Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective

Business Wire June 13, 2016

Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics

PR Newswire June 9, 2016

Boston Medical Center Avoids 8,500 tons of Carbon Annually by Leveraging Veolia's "Green Steam" Energy

PR Newswire June 9, 2016

Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society

Business Wire June 9, 2016

Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference

Business Wire May 31, 2016

Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters

Business Wire May 20, 2016

Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market

Business Wire May 18, 2016

Acorda Therapeutics Named One of the Best Places to Work for in New York

Business Wire May 4, 2016

Final Results of the Subsequent Offer Period of Acorda Therapeutics' Tender Offer for All of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp.

Business Wire May 2, 2016

Acorda Therapeutics to Present at Two Investor Conferences in May

Business Wire April 29, 2016

Acorda Provides Financial and Pipeline Update for First Quarter 2016

Business Wire April 28, 2016

Acorda Announces Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinson's Disease Published in Movement Disorders

Business Wire April 20, 2016

Completion of Acorda Therapeutics' Voluntary Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. and Matters Related Thereto

Business Wire April 18, 2016

Acorda to Host Conference Call to Discuss First Quarter 2016 on April 28, 2016

Business Wire April 14, 2016

Final Results of Acorda Therapeutics' Voluntary Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. and Commencement of a Subsequent Offer Period

Business Wire April 13, 2016

Acorda Therapeutics Announces Preliminary Tender Offer Results and Acceptance of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. Tendered in Tender Offer

Business Wire April 11, 2016

Phase 2b Data on Inhaled Levodopa CVT-301 Featured in Invited Science Session at American Academy of Neurology (AAN) Annual Meeting

Business Wire April 7, 2016

Acorda Therapeutics Supplements the Tender Offer Document Relating to the Voluntary Public Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. on 22 March 2016

Business Wire March 22, 2016

Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation to Continue in Delaware District Court

Business Wire March 21, 2016

Acorda Therapeutics Supplements Tender Offer Document Relating to the Voluntary Public Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies on 18 March 2016

Business Wire March 18, 2016